Skip to main content

Connect® MM- The Multiple Myeloma Disease Registry

Terminated · NCT01081028

Conditions: Multiple Myeloma

At a glance

Research payments reported, 2025
$29,711
U.S. investigators named
13
Sites paid
13
Planned or actual enrollment
3,011

About the trial

Sponsor
Celgene
Tested
First-line therapy (other), Second-line Multiple Myeloma treatments (drug)
Dates
Started 2009-09-01; completion 2024-12-31
Results posted
Not yet

The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

From ClinicalTrials.gov, last updated 2026-04-13. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $29,711 in research payments for this study in 2025 (13 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.